Author

G. Czerwieniec

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Tankasala· 1 shared B. Feierbach· 1 shared C. Guerrier· 1 shared C. H. Tay· 1 shared C. Snyder· 1 shared C.-W. Chu· 1 shared D. Barnes· 1 shared D. Tam· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Tankasala

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivAug 25, 2023

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

C.-W. Chu, T. Caval, F. Alisson-Silva…·F. Schwarz

This study shows that PD-1 glycosylation variants affect the efficacy of immune checkpoint inhibitors and suggests personalized therapeutic approaches.

DOI 10.26508/lsa.202302368

humanproteomics

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintJun 27, 2022

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

U. Schmitz, S. A. Gilmore, D. Tam…·B. Feierbach

This study identifies a KDM5 inhibitor with anti-HBV activity in vitro but not in vivo, highlighting challenges in translating epigenetic therapies to viral infections.

DOI 10.1101/2022.06.27.497732

humanmouse

𝕏 PostBluesky